1. Academic Validation
  2. Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors

Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors

  • Eur J Med Chem. 2015 Aug 28:101:525-33. doi: 10.1016/j.ejmech.2015.07.007.
Le-Mao Yu 1 Xiao-Ru Zhang 1 Xiao-Bing Li 1 Yuan Yang 1 Hong-Yu Wei 2 Xi-Xin He 2 Lian-Quan Gu 1 Zhi-Shu Huang 1 Yves Pommier 3 Lin-Kun An 4
Affiliations

Affiliations

  • 1 School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
  • 2 College of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
  • 3 Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-4255, United States.
  • 4 School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China. Electronic address: lssalk@mail.sysu.edu.cn.
Abstract

In our previous work, indolizinoquinolinedione derivative 1 was identified as a Top1 catalytic inhibitor. Herein, a series of 6-substituted indolizinoquinolinedione derivatives were synthesized through modification of the parent compound 1. Top1 cleavage and relaxation assays indicate that none of these novel compounds act as classical Top1 poison, and that the compounds with alkylamino terminus at C-6 side chain, including 8, 11-16, 18-21, 25, 26 and 28-30, are the most potent Top1 catalytic inhibitors. Top1-mediated unwinding assay demonstrated that 14, 22 and 26 were Top1 catalytic inhibitors without Top1-mediated unwinding effect. Moreover, MTT results showed that compounds 26, 28-30 exhibit significant cytotoxicity against human leukemia HL-60 cells, and that compound 26 exerts potent cytotoxicity against A549 lung Cancer cells at nanomolar range.

Keywords

Anticancer; DNA topoisomerase; Indolizinoquinolinedione; Inhibitor.

Figures